The value of gold salts as a treatment of rheumatoid disease is beyond dispute, and their more frequent and earlier use has been advocated.' Conventionally, gold injections are administered weekly until a total of 1 g has been reached and thereafter at less frequent intervals. 2 The importance of this maintenance period has been previously questioned,3 and the advantage over short courses was thought to be slight. 4 There is now compelling evidence that a more sustained improvement is obtained when (and indeed remission may not occur until) the patient has been receiving gold for 12 to 18 months.5
There is no consensus about the dose and frequency of gold injections needed to prevent relapse after 1 g has been given. It has been claimed that maintenance injections at 4-week intervals or longer are inadequate to maintain improvement6 and that serum gold levels must be kept above 300 ,Vg/dl during this period for maximum clinical benefit. 7 We have attempted to determine whether the response to maintenance gold injections given at 2-week intervals differs from the same dose administered every 4 weeks. In particular we have compared the clinical and radiological progression of the disease, the relative incidence of toxicity, and the relationship of serum gold level to relapse and side effects.
Patients and methods
Patients with rheumatoid arthritis were admitted to Six patients failed to complete the maintenance period, 4 on the 2-weekly regimen and 2 on the 4-weekly regimen. Ten patients (48 %) receiving fortnightly injections and 5 (22%) on the monthly injections developed toxicity. The relative frequency of adverse reactions is illustrated in Table 2 .
RELAPSES
The majority of patients either maintained or increased the improvements gained during the period of weekly injections. Relapse, however, occurred in 5 patients after 8 to 11 months of maintenance therapy, 3 receiving 2-weekly injections and 2 having 4-weekly injections. These patients were not characterised by any obvious clinical features, but 4 out of 5 were men. The mean and range of serum gold levels at 6 months were similar in those patients No. with nodules 7 7 Positive Rose-Waaler test 11(52 %) 12 (52%) There was an initial indication that more frequent maintenance injections were associated with a progressive decline in sedimentation rate, and in a preliminary report we speculated that this might imply a better clinical outcome.10 At the end of 1 year sedimentation rates were identical in the 2 groups, and our speculation was not substantiated. The larger number of patients with a reduction of rheumatoid factor titre following 2-weekly injections was not reflected in any clinical advantage in this group.
It was not possible to say whether the rate of radiological progression was retarded by maintenance injections. There was no difference between the two regimens in this respect, and, although five patients appeared t6 have an improved x-ray picture at the end of a year, the majority had deteriorated slightly. There is good evidence that chrysotherapy may modify or prevent erosive changes both in the early stages of the disease1 and over a longer period."1 Toxicity was greater in those patients receiving 2-weekly injections, though the differences were not statistically significant. Furst et al.12 noted a higher incidence of toxicity among patients receiving maintenance injections of 150 mg of sodium aurothiomalate compared with a lower dose, but they did not indicate whether the risks were also accentuated by more frequent injections. They failed to observe any relationship between side effects and serum gold levels, and this is in accordance with previous studies. 13 14 Our patients with the highest serum gold levels during maintenance treatment did not show an increased rate of side effects. The risk of gold toxicity diminishes with the duration of treatment but does not disappear completely. Kean and Anastassiades15 have shown that, for those who remit, gold treatment may be continued for up to 3 years with an increasing margin of safety.
It was notable that 5 patients in our study relapsed after 8 months of maintenance treatment. These had all done well up to that time, though none had completely remitted, and there was no evidence that their deterioration was related to the frequency of maintenance injections or serum gold levels. Four of these patients were men, but whether the disparity of sex distribution has any relevance cannot be determined on the basis of such small numbers. A tendency for some patients to deteriorate after prolonged periods of remission and despite continued chrysotherapy has been previously reported.15 It has been argued that maintenance injections beyond the total of 1 g of gold salts cannot influence the outcome and that improvements gained during a period of weekly injections may persist for variable periods thereafter.3 This is not the conventional view, and the value of maintenance injections has been convincingly demonstrated.5 However, it is disquieting to note the report of Rothermich et al. 16 in which it was stated that many patients who initially benefit from gold salts would deteriorate and that only 15% of patients continue with this treatment beyond 4 years. It is clear from our study that a maintenance dose of 50 mg at 2-weekly intervals confers no benefit over 50 mg per month and may enhance the risks of side effects. We made no attempt to determine'whether relapses can be mitigated by recourse to more frequent injections or larger doses of gold, nor do we suggest that monthly injections provide the ideal regimen.
There is an urgent need for more thorough appraisal of different maintenance schedules of chrysotherapy.
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